3-Amino-5-Phenylbenzamide EZH2 PROTACs for Low-Dose Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing EZH2 inhibitors require high doses to effectively inhibit enzyme activity and do not fully abolish the oncogenic functions of EZH2, which contributes to tumor growth, and there is a need for therapeutic agents that induce EZH2 degradation.
Innovation Solution
Development of substituted 3-amino-5-phenylbenzamide compounds that act as covalent inhibitors and can be derivatized into PROTACs to target EZH2 for degradation, utilizing a ligand for recruiting an E3 ubiquitin ligase to induce ubiquitination and proteasome-mediated degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing EZH2 inhibitors are used to inhibit enzyme activity, then EZH2 activity is suppressed, but very high doses are required and oncogenic functions are not fully abolished
Solution Approach 1:
The patent changes the mechanism of action from reversible inhibition to covalent bonding, fundamentally altering how the inhibitor interacts with EZH2. This parameter change allows for sustained inhibition at lower doses while addressing both enzymatic and non-enzymatic oncogenic functions through irreversible modification of the target protein
Solution Approach 2:
The invention combines multiple functional elements into a single covalent inhibitor molecule that can simultaneously address enzymatic activity and protein stability. The composite structure enables the compound to achieve both inhibition and degradation functions, eliminating the need for high doses required by conventional reversible inhibitors
2Reliability
If enzyme inhibitors are used to block EZH2 enzymatic function, then methyltransferase activity is inhibited, but non-enzymatic oncogenic functions remain active
Solution Approach 1:
The patent extracts the limitation of reversible inhibition by introducing covalent bonding capability. This extraction of the reversible-inhibition constraint allows the inhibitor to permanently modify EZH2, thereby eliminating both enzymatic and non-enzymatic oncogenic functions through irreversible modification and eventual protein degradation
Solution Approach 2:
Instead of accepting that enzymatic inhibition alone is sufficient, the invention inverts the approach by designing covalent inhibitors that permanently modify the target. This inversion transforms the inhibitor from a temporary blocker to a permanent modifier, thereby addressing non-enzymatic functions that persist under reversible inhibition
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds and PROTACs effectively inhibit EZH2 activity and induce its degradation in cells expressing EZH2, showing significant growth inhibition at low concentrations, while sparing cells without EZH2 expression, and are effective in treating various cancers.
Implementation Method 1
PROTACs include a ligand for recruiting an E3 ubiquitin ligase, a linker, and another ligand to bind with the protein targeted for degradation. Designed as such, PROTACs 'hijack' the E3 ubiquitin ligase to the protein which is targeted for protein degradation via ubiquitination
Implementation Method 2
proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of EZH2
Data Source
AI summary
Disclosed are covalent inhibitors of enhancer zeste homolog 2 (EZH2) which may be utilized as EZH2 targeting agents. The disclosed compounds may be characterized as substituted 3-amino-5-phenylbenzamide compounds. The disclosed compounds may be utilized as covalent inhibitors of EZH2 and further may be derivatized to form proteolysis-targeting chimeric molecules (PROTACs) that target EZH2 for degradation. The disclosed compounds and PROTACs may be used in pharmaceutical compositions and methods for treating cell proliferative disorders associated with EZH2 activity, such as cancer.